REBOA has been around in one form or another for decades. It was first used by vascular surgeons to gain control of pesky bleeding. It began its move into the trauma arena in 2011 with experimental use for major hemorrhage control in swine. After successful trials, it made the jump to humans in 2015.
Its use exploded over the following decade, peaking at 127 publications in 2021.

Trauma centers across the US were clamoring to be the first in their neighborhoods to get it. However, there were a few problems:
- It was not clear which patients would benefit from its usage.
- The number of patients who had significant bleeding below the diaphragm or from pelvic fractures was generally low in all but the busiest centers.
- There were significant vascular complications with disturbing frequency.
So what have we learned after about 2,000 published papers? The Eastern Association for the Surgery of Trauma (EAST) recently published another practice guideline to help us make good decisions. They conducted a systematic review and meta-analysis of 31 studies to answer six questions about REBOA use.
Here are the questions and their answers:
- In hemodynamically unstable trauma patients with suspected sub-diaphragmatic bleeding, should REBOA vs. no REBOA be performed before definitive hemostatic procedures to reduce time to definitive intervention, blood transfusion requirements, and mortality? (12 studies) Unfortunately, the evidence was of low quality due to selection bias, heterogeneity across studies, and wide confidence intervals resulting from small sample sizes. The review committee gave a conditional recommendation against using REBOA for these patients. The only randomized clinical trial available actually showed increased mortality in the REBOA group. The quality of the other studies was not enough to offset this.
- In hemodynamically unstable trauma patients with suspected pelvic fractures, should REBOA versus no REBOA be performed, before definitive hemostatic procedures, to decrease time to definitive intervention, blood transfusion requirements, and mortality? (11 studies) Once again, the quality of the papers reviewed was low. Similar to the question above, the committee gave a conditional recommendation against using REBOA in these patients.
- In trauma patients with cardiac arrest OR impending cardiac
arrest due to suspected subdiaphragmatic bleeding, should REBOA versus resuscitative thoracotomy be utilized to increase the rate of return of spontaneous circulation (ROSC), decrease time to aortic occlusion, and decrease mortality? (13 studies) Although patients receiving REBOA had 4x lower mortality, the quality and confounding factors were so significant that the committee could not make a recommendation for or against REBOA use in this population. - In trauma patients with cardiac arrest due to suspected subdiaphragmatic bleeding, should REBOA versus resuscitative thoracotomy be utilized to increase the rate of ROSC, decrease time to the aortic occlusion, and decrease mortality? (7 papers) This is a bit of slicing and dicing of the question. It applies only to patients in cardiac arrest and excludes those in whom it is “impending.” This reduced confounding data and demonstrated an identifiable decrease in mortality by more than half. Despite poor-quality data, the committee conditionally recommended the use of REBOA in this population.
- In hemodynamically unstable patients with subdiaphragmatic
bleeding of non-traumatic etiology, should REBOA versus no
REBOA be used prior to definitive hemostatic procedures, to decrease blood transfusion requirements and mortality? (1 paper) Given that there was only one paper and the quality of the data for analysis was low, the committee could not recommend for or against REBOA use in this group. - In hemodynamically stable patients with anticipated subdiaphragmatic bleeding due to placenta accreta syndrome (PAS), should REBOA vs no REBOA be performed prophylactically, prior to definitive hemostatic procedures, to decrease blood transfusion requirements and blood loss? (12 studies) The number of studies and their quality were very low, but REBOA use decreased packed red cell transfusion requirements by 3 units. The committee conditionally recommended for the use of REBOA for bleeding from placenta accreta. However, they cautioned about the possibility of complications from the procedure.
Bottom line: These recommendations are moving away from recommending REBOA for all cases with severe subdiaphragmatic or pelvic bleeding. In fact, they recommend its use only for patients actually in arrest or with placenta accreta. This last situation is very uncommon (approximately 1 in 400-500 pregnancies) but is increasing slowly over time. About half of these cases result in significant hemorrhage.
It’s time for most centers to start revising their REBOA protocols (if you have them). For high-volume centers, continue publishing your work to help us fine-tune the use of this valuable, but not invaluable, tool!
Reference: Resuscitative Endovascular Balloon Occlusion of the Aorta in surgical and trauma patients: a systematic review, meta-analysis and practice management guideline from the Eastern Association for the Surgery of Trauma. Trauma Surg Acute Care Open. 2025 Mar 28;10(1):e001730. doi: 10.1136/tsaco-2024-001730. PMID: 40166770; PMCID: PMC11956280.